Vericel to Host Third-Quarter 2015 Earnings Webcast and Conference Call on November 13, 2015
November 03 2015 - 4:01PM
Vericel Corporation (NASDAQ:VCEL), a leading developer of
patient-specific expanded cellular therapies for the treatment of
severe diseases and conditions, today announced the following
webcast and conference call:
What: |
Vericel Corporation Third-Quarter
2015 Earnings Call |
When: |
Friday, November 13, 2015 at
8:00am (ET) |
Where: |
http://investors.vcel.com/events.cfm |
How: |
The conference call will be
available live in the Investors section of the Vericel website at
http://investors.vcel.com/events.cfm. Please access the site at
least 15 minutes prior to the scheduled start time in order to
download the required audio software if necessary. |
|
|
|
|
To participate in the live call by
telephone, please call (877) 312-5881 and reference Vericel
Corporation third-quarter 2015 investor conference call. If
calling from outside the U.S., please use the international phone
number (253) 237-1173. |
If you are unable to participate in the live call, the webcast
will be available at http://investors.vcel.com/events.cfm until
Monday, November 14, 2016. A replay of the call will also be
available until 11:59 pm (EDT) on 11/17/2015 23:59, 2015 by calling
(855) 859-2056, or from outside the U.S. (404) 537-3406. The
conference ID is 71018424.
About Vericel Corporation
Vericel Corporation (formerly Aastrom Biosciences, Inc.) is a
leader in developing patient-specific expanded cellular therapies
for use in the treatment of patients with severe diseases and
conditions. The company markets two autologous cell therapy
products in the U.S.: Carticel® (autologous cultured chondrocytes),
an autologous chondrocyte implant for the treatment of cartilage
defects in the knee, and Epicel® (cultured epidermal autografts), a
permanent skin replacement for the treatment of patients with
deep-dermal or full-thickness burns comprising greater than or
equal to 30% of total body surface area. Vericel is also developing
MACI™, a third-generation autologous chondrocyte implant for the
treatment of cartilage defects in the knee, and ixmyelocel-T, a
patient-specific multicellular therapy for the treatment of
advanced heart failure due to ischemic dilated cardiomyopathy. For
more information, please visit the company's website at
www.vcel.com.
CONTACT: Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
or
Lee Stern
The Trout Group
lstern@troutgroup.com
(646) 378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024